Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-100 in Renal Transplant Patients with IF/TA
NCT00878761Phase 2Withdrawn
- Sponsor
- Stromedix
- Start
- Sep 2010
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of STX-100 in chronic allograft dysfunction (CAD), sponsored by Stromedix. Planned start Sep 2010; status: withdrawn.
02
Drugs
STX-100
03
Conditions
chronic allograft dysfunction (CAD)
Beyond the preview
Go deeper on NCT00878761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00878761.